{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:24:34Z","timestamp":1762410274353,"version":"build-2065373602"},"reference-count":112,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTM"],"abstract":"<jats:p>This comprehensive review explores two antiretroviral drugs, Etravirine (ETV) and Darunavir (DRV), a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor, that are commonly used in human immunodeficiency virus (HIV) infection treatment, often in combination with each other. The pharmacokinetic properties of these drugs are covered as well as the clinical trials of these two drugs combined. This paper also delves into the possible repurposing of these two drugs for other diseases, with drug repurposing being a significant factor in addressing global health challenges. DRV was extensively studied for treating COVID-19, as well as other infections, such as candidiasis and cryptococcosis, while ETV proved to be efficient in hampering Zika virus brain infection. The focus on cancer repurposing is also explored, with the results revealing that ETV has a particular inhibitory effect on ovarian cancer in vitro and on cancer molecules, such as anterior gradient protein 2 homolog (AGR2) and casein kinase 1 (CK1\u03b5), and that DRV has an in silico inhibitory effect on human lactate dehydrogenase A (LDHA) and induces the in vitro and in vivo inhibition of pepsin, consequent laryngopharyngeal reflux, and possible laryngeal and hypopharyngeal carcinomas. The significance of fresh methods of drug development is emphasized in this work, as is the enormous potential for new therapeutic uses of the antiretroviral drugs ETV and DRV in viral and non-viral disorders.<\/jats:p>","DOI":"10.3390\/ijtm3040032","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:18:52Z","timestamp":1698405532000},"page":"461-478","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-1459","authenticated-orcid":false,"given":"Mariana","family":"Pereira","sequence":"first","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"ICBAS, School of Medicine and Biomedical Sciences, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.4449","article-title":"HIV and the spectrum of human disease","volume":"235","author":"Lucas","year":"2015","journal-title":"J. Pathol."},{"key":"ref_2","unstructured":"UNAIDS (2023, July 17). Global HIV & AIDS Statistics\u2014Fact Sheet. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0011-8532(03)00016-8","article-title":"HIV disease","volume":"47","author":"Patton","year":"2003","journal-title":"Dent. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","article-title":"Pathogenic mechanisms of HIV disease","volume":"6","author":"Moir","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_5","first-page":"5","article-title":"HIV virology and pathogenetic mechanisms of infection: A brief overview","volume":"46","author":"Raimondo","year":"2010","journal-title":"Ann. Ist. Super. Sanita"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0000000000000588","article-title":"HIV treatment and prevention 2019: Current standards of care","volume":"15","author":"Phanuphak","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_7","unstructured":"EMA (2023, July 18). Intelence. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/intelence."},{"key":"ref_8","unstructured":"FDA (2023, July 18). INTELENCE\u00ae (Etravirine) Tablets for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022187s009lbl.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine","volume":"48","author":"Kakuda","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e64776","DOI":"10.7554\/eLife.64776","article-title":"HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells","volume":"10","author":"Zila","year":"2021","journal-title":"Elife"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/dmd.111.044404","article-title":"Biotransformation of the antiretroviral drug etravirine: Metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism","volume":"40","author":"Yanakakis","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","unstructured":"Bank, D. (2023, July 18). Etravirine. Available online: https:\/\/go.drugbank.com\/drugs\/DB06414."},{"key":"ref_14","unstructured":"FDA (2023, July 04). PREZISTA (Darunavir), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021976s021lbl.pdf."},{"key":"ref_15","unstructured":"EMA (2023, July 19). Prezista. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prezista."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0083-6729(00)58026-1","article-title":"HIV protease: Enzyme function and drug resistance","volume":"58","author":"Gulnik","year":"2000","journal-title":"Vitam. Horm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"Azijn","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/dmd.108.024109","article-title":"Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects","volume":"37","author":"Vermeir","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/14656561003724754","article-title":"Etravirine in combination with darunavir\/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients","volume":"11","author":"Hull","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/135965350701200511","article-title":"Pharmacokinetics of darunavir\/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers","volume":"12","author":"Kakuda","year":"2007","journal-title":"Antivir. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/QAD.0b013e3283316a5e","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials","volume":"23","author":"Katlama","year":"2009","journal-title":"Aids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3851\/IMP1662","article-title":"Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials","volume":"15","author":"Katlama","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1310\/hct1504-140","article-title":"Efficacy and safety of darunavir\/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: A multicenter clinical experience","volume":"15","author":"Gazzola","year":"2014","journal-title":"HIV Clin. Trials"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/hiv.12211","article-title":"The Intelence aNd pRezista Once A Day Study (INROADS): A multicentre, single-arm, open-label study of etravirine and darunavir\/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects","volume":"16","author":"Ruane","year":"2015","journal-title":"HIV Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jac\/dkx459","article-title":"Pharmacokinetics of darunavir\/cobicistat and etravirine alone and co-administered in HIV-infected patients","volume":"73","author":"Curran","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"Lindemans","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Belkhir, L., Elens, L., Zech, F., Panin, N., Vincent, A., Yombi, J.C., Vandercam, B., and Haufroid, V. (2016). Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165631"},{"key":"ref_33","unstructured":"HIV.gov (2023, July 25). Pre-Exposure Prophylaxis, Available online: https:\/\/www.hiv.gov\/hiv-basics\/hiv-prevention\/using-hiv-medication-to-reduce-risk\/pre-exposure-prophylaxis\/."},{"key":"ref_34","first-page":"535","article-title":"Emtricitabine\/tenofovir (Truvada) for HIV prophylaxis","volume":"88","author":"Coutinho","year":"2013","journal-title":"Am. Fam. Physician"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/cid\/civ778","article-title":"No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting","volume":"61","author":"Volk","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/QAD.0000000000000613","article-title":"The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs","volume":"29","author":"Martin","year":"2015","journal-title":"Aids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV Preexposure Prophylaxis: A Review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/cix593","article-title":"Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures","volume":"65","author":"Marcus","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","first-page":"545","article-title":"Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection","volume":"107","author":"Erlich","year":"2023","journal-title":"Am. Fam. Physician"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: Results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Hughes","year":"2022","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Duwal, S., Dickinson, L., Khoo, S., and von Kleist, M. (2019). Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. PLoS Comput. Biol., 15.","DOI":"10.1371\/journal.pcbi.1006740"},{"key":"ref_48","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2015). Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases (Eighth Edition), W.B. Saunders."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0b013e31825cb645","article-title":"Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men","volume":"61","author":"Brown","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bhattacharya, S., Sae-Tia, S., and Fries, B.C. (2020). Candidiasis and Mechanisms of Antifungal Resistance. Antibiotics, 9.","DOI":"10.3390\/antibiotics9060312"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Taverne-Ghadwal, L., Kuhns, M., Buhl, T., Schulze, M.H., Mbaitolum, W.J., Kersch, L., Weig, M., Bader, O., and Gro\u00df, U. (2022). Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.844069"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.3390\/cimb44110364","article-title":"Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study","volume":"44","author":"Fenley","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","article-title":"Cryptococcus: From environmental saprophyte to global pathogen","volume":"14","author":"May","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_55","unstructured":"World Health Organization (2023, July 18). Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241550277."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1139\/w2012-075","article-title":"Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans","volume":"58","author":"Sidrim","year":"2012","journal-title":"Can. J. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1099\/jmm.0.001194","article-title":"Darunavir inhibits Cryptococcus neoformans\/Cryptococcus gattii species complex growth and increases the susceptibility of biofilms to antifungal drugs","volume":"69","author":"Brilhante","year":"2020","journal-title":"J. Med. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3201\/eid2207.151990","article-title":"A Literature Review of Zika Virus","volume":"22","author":"Plourde","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika Virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"O595","DOI":"10.1111\/1469-0691.12707","article-title":"Rapid spread of emerging Zika virus in the Pacific area","volume":"20","author":"Musso","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: A systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/uog.15831","article-title":"Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: Tip of the iceberg?","volume":"47","author":"Malinger","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_63","unstructured":"PAHO (2023, July 25). Epidemiological Alert, Neurological Syndrome, Congenital Malformations, and Zika Virus Infection. Implications for Public Health in the Americas (1 December 2015). Available online: https:\/\/iris.paho.org\/handle\/10665.2\/50697?show=full."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00018-018-2751-x","article-title":"Structure and function of Zika virus NS5 protein: Perspectives for drug design","volume":"75","author":"Wang","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.ymthe.2019.10.006","article-title":"Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine","volume":"27","author":"Sariyer","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"919","DOI":"10.15252\/embj.201696241","article-title":"The crystal structure of Zika virus NS5 reveals conserved drug targets","volume":"36","author":"Duan","year":"2017","journal-title":"Embo J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1074\/jbc.M115.710731","article-title":"A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening","volume":"291","author":"Noble","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","article-title":"A Mouse Model of Zika Virus Pathogenesis","volume":"19","author":"Lazear","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2014The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-020-0190-2","article-title":"Overview of lethal human coronaviruses","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","article-title":"Human Coronavirus: Host-Pathogen Interaction","volume":"73","author":"Fung","year":"2019","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/cpnc.70","article-title":"Label-Free Electrophoretic Mobility Shift Assay (EMSA) for Measuring Dissociation Constants of Protein-RNA Complexes","volume":"76","author":"Seo","year":"2019","journal-title":"Curr. Protoc. Nucleic Acid. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1080\/07391102.2020.1757510","article-title":"Peptide-like and small-molecule inhibitors against COVID-19","volume":"39","author":"Pant","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/1386207323666200814132149","article-title":"Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19","volume":"24","author":"Talluri","year":"2021","journal-title":"Comb. Chem. High. Throughput Screen."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1080\/07391102.2020.1751298","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach","volume":"39","author":"Khan","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23450","DOI":"10.1039\/D1RA03956C","article-title":"Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2","volume":"11","author":"Silva","year":"2021","journal-title":"RSC Adv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1080\/07391102.2020.1791958","article-title":"In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors","volume":"39","author":"Ibrahim","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Velagacherla, V., Suresh, A., Mehta, C.H., Nayak, U.Y., and Nayak, Y. (2023). Multi-Targeting Approach in Selection of Potential Molecule for COVID-19 Treatment. Viruses, 15.","DOI":"10.3390\/v15010213"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.imu.2021.100531","article-title":"Identification of potential antivirals against SARS-CoV-2 using virtual screening method","volume":"23","author":"Rahman","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Halder, U.C. (2021). Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins. J. Biol. Res., 28.","DOI":"10.1186\/s40709-021-00149-2"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Sahoo, A., Swain, S.S., Paital, B., and Panda, M. (2022). Combinatorial approach of vitamin C derivative and anti-HIV drug-darunavir against SARS-CoV-2. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2701010"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/prot.26341","article-title":"Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro","volume":"90","author":"Swain","year":"2022","journal-title":"Proteins"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12985-020-01457-0","article-title":"Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2\u2019s main protease","volume":"17","author":"Mahdi","year":"2020","journal-title":"Virol. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3851\/IMP2722","article-title":"Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients","volume":"19","author":"Lluch","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-020-00933-8","article-title":"Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6","volume":"59","author":"Cojutti","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: Suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"173634","DOI":"10.1016\/j.ejphar.2020.173634","article-title":"Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment","volume":"889","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"ofaa241","DOI":"10.1093\/ofid\/ofaa241","article-title":"Antiviral Activity and Safety of Darunavir\/Cobicistat for the Treatment of COVID-19","volume":"7","author":"Chen","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jiph.2020.10.015","article-title":"Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach","volume":"13","author":"Indu","year":"2020","journal-title":"J. Infect. Public. Health"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3727\/096504017X14905635363102","article-title":"Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs","volume":"25","author":"Perna","year":"2017","journal-title":"Oncol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Shamloo, B., and Usluer, S. (2019). p21 in Cancer Research. Cancers, 11.","DOI":"10.3390\/cancers11081178"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2867-3-17","article-title":"Tumor suppressor gene E-cadherin and its role in normal and malignant cells","volume":"3","year":"2003","journal-title":"Cancer Cell Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ydbio.2012.06.030","article-title":"The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development","volume":"369","author":"Verma","year":"2012","journal-title":"Dev. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1165\/rcmb.2011-0421OC","article-title":"AGR2 is induced in asthma and promotes allergen-induced mucin overproduction","volume":"47","author":"Schroeder","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.gene.6364263","article-title":"Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease","volume":"7","author":"Zheng","year":"2006","journal-title":"Genes. Immun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e05000","DOI":"10.1016\/j.heliyon.2020.e05000","article-title":"Secretion of pro-oncogenic AGR2 protein in cancer","volume":"6","author":"Moidu","year":"2020","journal-title":"Heliyon"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.bbadis.2018.01.021","article-title":"Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-\u03baB pathway","volume":"1864","author":"Jia","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ly, T.T.G., Yun, J., Ha, J.S., Kim, Y.J., Jang, W.B., Van Le, T.H., Rethineswaran, V.K., Choi, J., Kim, J.H., and Min, S.H. (2022). Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020944"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"C\u00f3rdova-Bahena, L., S\u00e1nchez-\u00c1lvarez, A.A., Ruiz-Moreno, A.J., and Velasco-Vel\u00e1zquez, M.A. (2021). Repositioning of Etravirine as a Potential CK1\u03b5 Inhibitor by Virtual Screening. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010008"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1111\/j.1742-4658.2006.05462.x","article-title":"Site-specific casein kinase 1epsilon-dependent phosphorylation of Dishevelled modulates beta-catenin signaling","volume":"273","author":"Klimowski","year":"2006","journal-title":"Febs J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Paul, S.K., Dutta Chowdhury, K., Dey, S.R., Paul, A., and Haldar, R. (2022). Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: A computational approach. J. Biomol. Struct. Dyn., 1\u201310.","DOI":"10.1080\/07391102.2022.2158134"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1002\/cam4.1820","article-title":"Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy","volume":"7","author":"Feng","year":"2018","journal-title":"Cancer Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21053\/ceo.2020.00465","article-title":"Pepsin and Laryngeal and Hypopharyngeal Carcinomas","volume":"14","author":"Yin","year":"2021","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lary.30242","article-title":"Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model","volume":"133","author":"Johnston","year":"2023","journal-title":"Laryngoscope"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1080\/07391102.2022.2097312","article-title":"Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: A computational drug discovery and in vitro insight","volume":"41","author":"Swami","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-018-0904-2","article-title":"Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells","volume":"37","author":"Veschi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Costa, B., and Vale, N. (2022). Efavirenz: History, Development and Future. Biomolecules, 13.","DOI":"10.3390\/biom13010088"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Hecht, M., Erber, S., Harrer, T., Klinker, H., Roth, T., Parsch, H., Fiebig, N., Fietkau, R., and Distel, L.V. (2015). Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130277"}],"container-title":["International Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-8937\/3\/4\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:36Z","timestamp":1760130756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-8937\/3\/4\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":112,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijtm3040032"],"URL":"https:\/\/doi.org\/10.3390\/ijtm3040032","relation":{},"ISSN":["2673-8937"],"issn-type":[{"type":"electronic","value":"2673-8937"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}